Information Provided By: 
Fly News Breaks for June 27, 2017
NVS, KITE
Jun 27, 2017 | 07:13 EDT
Canaccord analyst John Newman said Kite Pharma (KITE) has a quicker turnaround time for its axi-cel CART therapy for DLBCL versus its competition, which should translate into a commercial advantage for them. The meaningful manufacturing capability gives it a clear advantage over competitor Novartis (NVS), said Newman, who reiterated his Buy rating and raised his price target to $115 from $90 on Kite shares.
News For KITE;NVS From the Last 2 Days
NVS
Apr 23, 2024 | 06:36 EDT
